Lilly picks Pennsylvania for $3.5 billion plant making injectable obesity drugs including retatrutide

Eli Lilly will put more than $3.5 billion into a new injectable-drug factory in Lehigh County, Pennsylvania, the company announced Jan. 30, 2026. The site, in Fogelsville, is intended to produce next-generation weight-loss therapies, among them retatrutide — an experimental medicine that Lilly describes as a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist ^[1][4].

This is the fourth new U.S. manufacturing location Lilly has announced since February 2025, and the 10th the Indianapolis-based company has announced since 2020 ^[1][4]. Reuters reported the plant falls under a pledge Lilly made in 2025 to spend more than $27 billion on four new U.S. sites ^[2]. Lilly says its capital commitments since 2020 now top $50 billion, covering new plants in Alabama, Pennsylvania, Texas, Virginia, North Carolina and Indiana, plus the Lilly Medicine Foundry, expansions in Puerto Rico and Indianapolis, and a Wisconsin site the company acquired ^[1][4].

Lilly expects to employ 850 people in the Lehigh Valley — engineers, scientists, operations staff and laboratory technicians — and says building the plant will generate about 2,000 construction jobs ^[1][4]. Work is scheduled to start in 2026, and the facility is not expected to be running until 2031 ^[1][4]. Pennsylvania's economic development department describes the hiring as "at least 850 new jobs over the next five years" ^[3].

Gov. Josh Shapiro said the state is committing $100 million to the project and called it the largest life-sciences investment in the Commonwealth's history ^[2][3]. According to the state, the package includes as much as $50 million in tax credits under the PA Edge program, a $25 million grant from the PA SITES program and a $25 million Pennsylvania First grant, plus up to $5 million for a workforce-training program run with a local community college or technical school ^[3]. Lilly also gets permitting help through the state's PA Permit Fast Track Program ^[3], and Reuters reported Shapiro said officials are working to keep permits moving quickly ^[2].

Lilly said it chose the Fogelsville location from more than 300 candidates, citing nearby STEM universities, an existing technical manufacturing base, and available utilities and transportation ^[1][4]. The company plans to use AI, machine learning, integrated monitoring and data analytics at the site and to partner with Pennsylvania universities on training ^[1][4].

Reuters reported that drugmakers are expanding U.S. production as President Donald Trump has threatened tariffs on imported pharmaceuticals, and that Lilly, Pfizer and Merck have each promised billions in domestic spending ^[2]. Lilly CEO David Ricks told a Friday press conference in Allentown that the sites "will be really state of the art manufacturing to last many decades to come," adding, "We're finding these medicines are quite popular, but we still have work to do to expand access, to improve affordability" ^[2]. Edgardo Hernandez, who leads Lilly's manufacturing operations, said the plant "will increase access to next-generation weight-loss treatments and improve the domestic supply of essential medicines for current and future patients" ^[1][4].

Why it matters for patients

Prescriptions filled today are not affected by this announcement. The plant is not scheduled to run until 2031, and Lilly has not said how much medicine it will produce or whether that output would change prices ^[1][4]. Ricks said Friday that more work remains on access and affordability ^[2].

Retatrutide is not approved for sale and cannot be prescribed ^[1][4]. Reuters reported that it outperformed Lilly's marketed obesity drug Zepbound, which is tirzepatide, in a late-stage trial ^[2]. Even so, when or whether patients could get retatrutide would depend on an FDA review that Lilly has not described. Nor has the company said whether the Pennsylvania plant would make any medicine it sells now, such as Mounjaro or Zepbound, or how much of its output is aimed at the U.S. market.

What happens next

Construction is expected to begin in 2026, with the site targeted to be operational in 2031 ^[1][4]. Separately, Reuters reported Lilly plans to launch a weight-loss pill in several countries at a $150-a-month cash price and is pursuing U.S. approval "in the coming months" ^[2]. Whether that pill would be made in Pennsylvania has not been reported.